Tauriga Sciences, Inc. CEO Seth M. Shaw to Deliver Presentation on Cannabis Investments at the NY TradersEXPO on March 9th at 9:00am EST
The Presentation is Titled: “Differentiating from Competitors and Establishing Barriers to Entry in the Nascent CBD Edibles Sector”NEW YORK, NY, March 02, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that its Chief Executive Officer (“CEO”), Mr. Seth M. Shaw, will deliver the presentation on Cannabis Investments at the NY TradersEXPO (“MoneyShow”) on March 9, 2020 at 9:00am EST. This presentation will be half an hour long and take place at the New York Marriot Hotel – at the Brooklyn Bridge. The Company is also operating a main floor Exhibitor Booth (# 211) at this NY TradersEXPO Tradeshow and expects to interact with a number of potential new investors. This presentation, titled: “Differentiating from Competitors and Establishing Barriers to Entry in the Nascent CBD Edibles Sector,” is expected to be attended by several hundred accredited individual and institutional investors and provides the Company with an opportunity to expand both its investor and market awareness. Link to Presentation: https://conferences.moneyshow.com/tradersexpo-new-york/speakers/7008e3674d354293a191431396539b50/seth-shaw/?scode=049647In other news, the Company continues to progress in its efforts to develop a Pharmaceutical grade version of Tauri-Gum™ and expects to update shareholders in the near future. This proposed Pharmaceutical product is focused on Nausea Regulation, specifically pertaining to patients subjected to ongoing chemotherapy treatment. During January 2020, the Company retained the law firm of Lowenstein Sandler LLP to assist it in these efforts.ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™. The Company is currently in production of three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and POMEGRANATE. On December 6, 2019 the Company announced that it completed the initial production run (thereby expanding its existing product lines) with the introduction of a 25mg Vegan CBD Isolate Infused vegan gummy (“gum drop”), branded under the name: Tauri-Gummies™. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com.
The Company has also announced the development of a Cannabigerol (“CBG”) Isolate infused version of Tauri-Gum™. The flavor that has been selected is Starfruit/Peach and each piece of gum will contain 10mg of CBG Isolate / Each blister pack will contain 80mg of CBG Isolate. The Company expects to commence production during its 4thFiscal Quarter of 2020 (January 1, 2020 – March 31, 2020).
In addition, on March 11, 2019, the Company announced the official launch of its E-Commerce site – as part of its Tauri-Gum™ commercialization strategy. This site can be accessed by visiting the following URL address: www.taurigum.com
The Company has established corporate offices in both New York City (USA) and Barcelona (Spain).
DISCLAIMER — Forward-Looking StatementsThere can be no guarantee that the Company will ultimately be successful, in developing any type of Pharmaceutical product(s).Contact:CONTACT INFORMATION